Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications
Acute Lymphoblastic Leukemia (ALL) is the predominant hematological malignancy in pediatric populations, originating from B- or T-cell precursors within the bone marrow. The disease exhibits a high degree of heterogeneity, both at the molecular level and in terms of clinical presentation. A complex...
Main Authors: | Alan Jhones Barbosa Assis, Brunna Letícia de Oliveira Santana, Ana Cristina Moura Gualberto, Fabio Pittella-Silva |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1322937/full |
Similar Items
-
Targeted genome editing in acute lymphoblastic leukemia: a review
by: Adrián Montaño, et al.
Published: (2018-07-01) -
CRISPR/Cas9 in Chronic Lymphocytic Leukemia
by: María Hernández-Sánchez
Published: (2022-05-01) -
Various Aspects of a Gene Editing System—CRISPR–Cas9
by: Edyta Janik, et al.
Published: (2020-12-01) -
The CRISPR/Cas system: Gene Editing by bacterial defense
by: Amira H. El-Ashry
Published: (2023-09-01) -
Targeting lactate dehydrogenase A (LDHA) exerts antileukemic effects on T‐cell acute lymphoblastic leukemia
by: Haizhi Yu, et al.
Published: (2020-10-01)